Acurx Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACXP research report →
Companywww.acurxpharma.com
Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections.
- CEO
- David Luci
- IPO
- 2021
- Employees
- 4
- HQ
- Staten Island, NY, US
Price Chart
Valuation
- Market Cap
- $3.00M
- P/E
- -0.38
- P/S
- 0.00
- P/B
- 0.40
- EV/EBITDA
- 0.82
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -153.93%
- ROIC
- -108.82%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-7,966,538 · 43.51%
- EPS
- $-5.32 · 69.76%
- Op Income
- $-8,091,983
- FCF YoY
- -65271.28%
Performance & Tape
- 52W High
- $21.00
- 52W Low
- $1.33
- 50D MA
- $3.09
- 200D MA
- $3.73
- Beta
- -2.09
- Avg Volume
- 3.20M
Get TickerSpark's AI analysis on ACXP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 20, 26 | Sailer Carl | other | 2,150 |
| Apr 20, 26 | DEAN JACK H | other | 2,150 |
| Apr 20, 26 | Donohue James J. | other | 2,150 |
| Apr 20, 26 | HARRISON THOMAS L | other | 2,150 |
| Apr 20, 26 | Scodari Joseph C | other | 2,150 |
| Apr 20, 26 | DELUCCIA ROBERT J | other | 37,100 |
| Apr 20, 26 | LUCI DAVID P | other | 37,100 |
| Apr 20, 26 | Shawah Robert G. | other | 25,900 |
| Feb 5, 25 | Shawah Robert G. | other | 145,500 |
| Feb 5, 25 | LUCI DAVID P | other | 250,000 |
Our ACXP Coverage
We haven't published any research on ACXP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ACXP Report →